Halozyme Therapeutics, Inc.
Index- P/E17.62 EPS (ttm)2.52 Insider Own0.70% Shs Outstand137.94M Perf Week2.65%
Market Cap6.16B Forward P/E14.44 EPS next Y3.08 Insider Trans0.00% Shs Float136.31M Perf Month-7.72%
Income366.20M PEG0.57 EPS next Q0.51 Inst Own97.40% Short Float6.69% Perf Quarter6.69%
Sales487.50M P/S12.64 EPS this Y200.60% Inst Trans1.43% Short Ratio7.38 Perf Half Y32.22%
Book/sh2.13 P/B20.88 EPS next Y53.54% ROA28.00% Target Price49.50 Perf Year7.78%
Cash/sh1.51 P/C29.43 EPS next 5Y31.00% ROE141.90% 52W Range31.36 - 52.98 Perf YTD10.62%
Dividend- P/FCF21.23 EPS past 5Y40.20% ROI38.10% 52W High-16.04% Beta1.19
Dividend %- Quick Ratio2.20 Sales past 5Y24.80% Gross Margin81.50% 52W Low41.84% ATR2.02
Employees145 Current Ratio2.70 Sales Q/Q11.60% Oper. Margin49.60% RSI (14)42.02 Volatility5.47% 4.16%
OptionableYes Debt/Eq4.25 EPS Q/Q-74.30% Profit Margin75.10% Rel Volume7.23 Prev Close43.09
ShortableYes LT Debt/Eq3.91 EarningsAug 16 BMO Payout0.00% Avg Volume1.24M Price44.48
Recom2.40 SMA20-6.29% SMA50-4.89% SMA20010.76% Volume8,924,214 Change3.23%
May-23-22Initiated SVB Leerink Outperform $52
Jun-14-21Initiated Evercore ISI Outperform
May-17-21Initiated SVB Leerink Outperform $56
May-11-21Downgrade Piper Sandler Overweight → Neutral $50 → $48
Jan-21-21Reiterated The Benchmark Company Buy $46 → $59
Dec-17-20Initiated Berenberg Buy $50
Sep-14-20Resumed JP Morgan Overweight $28
Jul-01-20Initiated The Benchmark Company Buy $39
Feb-05-20Upgrade Piper Sandler Neutral → Overweight $18 → $27
Jan-09-20Upgrade BMO Capital Markets Market Perform → Outperform $17 → $24
Jan-08-20Initiated Goldman Buy $24
Nov-05-19Upgrade Barclays Underweight → Equal Weight $17 → $16
Oct-19-18Resumed Piper Jaffray Neutral
May-11-18Downgrade Barclays Equal Weight → Underweight $19
Jan-24-18Initiated Goldman Neutral
Oct-16-17Reiterated Piper Jaffray Overweight $26 → $29
Jan-06-17Downgrade Citigroup Buy → Neutral
Nov-03-16Initiated Deutsche Bank Buy $12
Dec-04-15Initiated Wells Fargo Outperform
Nov-18-15Initiated Citigroup Buy
Aug-15-22 10:32PM  
Aug-10-22 03:13PM  
Aug-09-22 06:15PM  
Aug-02-22 12:55AM  
Jul-26-22 08:30AM  
Jul-13-22 09:14AM  
Jul-08-22 07:22AM  
Jul-06-22 08:08AM  
Jul-01-22 01:13PM  
Jun-27-22 06:15AM  
Jun-21-22 09:13AM  
Jun-09-22 11:30AM  
Jun-08-22 08:30AM  
Jun-07-22 08:30AM  
Jun-06-22 06:55AM  
May-25-22 09:40AM  
May-24-22 08:30AM  
May-19-22 12:15PM  
May-17-22 10:44AM  
May-16-22 09:40AM  
May-12-22 09:26AM  
May-11-22 09:36AM  
May-10-22 05:25PM  
May-09-22 09:35AM  
May-04-22 08:45AM  
May-03-22 02:20PM  
Apr-26-22 08:00AM  
Apr-22-22 10:22AM  
Apr-14-22 01:34PM  
Apr-13-22 04:16PM  
Apr-06-22 08:24AM  
Apr-01-22 08:30AM  
Mar-30-22 06:30AM  
Mar-25-22 09:47AM  
Mar-24-22 11:30AM  
Mar-23-22 08:42AM  
Mar-22-22 12:22PM  
Mar-21-22 08:30AM  
Mar-18-22 07:20PM  
Mar-17-22 06:00AM  
Mar-15-22 04:01PM  
Feb-27-22 11:00PM  
Feb-23-22 11:31AM  
Feb-22-22 05:25PM  
Feb-15-22 03:01PM  
Feb-09-22 08:00AM  
Feb-03-22 08:08AM  
Feb-02-22 04:43PM  
Jan-31-22 01:38PM  
Jan-13-22 09:15AM  
Jan-10-22 08:00AM  
Jan-04-22 08:00AM  
Dec-24-21 11:38PM  
Dec-22-21 06:15AM  
Dec-17-21 05:46PM  
Dec-13-21 04:05PM  
Dec-09-21 04:01PM  
Dec-07-21 01:51PM  
Dec-06-21 11:32AM  
Dec-02-21 11:31AM  
Dec-01-21 02:21PM  
Nov-18-21 09:00AM  
Nov-05-21 09:38AM  
Nov-03-21 11:42AM  
Nov-02-21 05:35PM  
Nov-01-21 08:46AM  
Oct-28-21 12:10PM  
Oct-26-21 04:53PM  
Oct-19-21 04:05PM  
Oct-05-21 10:27AM  
Oct-04-21 11:54AM  
Sep-15-21 04:05PM  
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LaBarre Michael J.SVP, Chief Technical OfficerFeb 15Option Exercise0.003,3860174,307Feb 17 06:04 PM
LaBrosse NicoleSVP, Chief Financial OfficerFeb 15Option Exercise0.001,25509,478Feb 17 06:03 PM
Torley HelenPresident and CEOFeb 15Option Exercise0.0013,0920594,069Feb 17 06:02 PM
LaBrosse NicoleSVP, Chief Financial OfficerFeb 14Option Exercise0.001,25608,650Feb 14 07:28 PM
Torley HelenPresident and CEOFeb 14Option Exercise0.0028,7290596,102Feb 14 07:27 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 14Option Exercise0.005,7710172,916Feb 14 07:29 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 12Option Exercise0.007,8830169,870Feb 14 07:29 PM
Torley HelenPresident and CEOFeb 12Option Exercise0.0032,7950584,639Feb 14 07:27 PM
LaBrosse NicoleSVP, Chief Financial OfficerFeb 12Option Exercise0.001,38907,900Feb 14 07:28 PM
LaBrosse NicoleSVP, Chief Financial OfficerFeb 10Option Exercise0.002,50307,536Feb 14 07:28 PM
Torley HelenPresident and CEOFeb 10Option Exercise0.0031,2820568,442Feb 14 07:27 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 10Option Exercise0.008,1330164,979Feb 14 07:29 PM
Torley HelenPresident and CEONov 08Option Exercise14.6650,000733,000587,160Nov 08 06:22 PM
Torley HelenPresident and CEONov 08Sale39.8250,0001,990,768537,160Nov 08 06:22 PM
MATSUI CONNIEDirectorNov 05Sale40.3832,0001,292,113181,983Nov 05 05:59 PM
LaBarre Michael J.SVP, Chief Technical OfficerOct 12Option Exercise13.108,050105,455156,846Oct 12 07:06 PM
Torley HelenPresident and CEOOct 04Option Exercise14.6650,000733,000587,160Oct 04 07:37 PM
Torley HelenPresident and CEOOct 04Sale40.0950,0002,004,390537,160Oct 04 07:37 PM
LaBarre Michael J.SVP, Chief Technical OfficerOct 01Option Exercise13.1029,450385,795178,246Oct 01 07:32 PM
LaBarre Michael J.SVP, Chief Technical OfficerOct 01Sale39.9329,4501,175,968148,796Oct 01 07:32 PM
Torley HelenPresident and CEOSep 07Option Exercise14.6650,000733,000587,160Sep 07 05:46 PM
Torley HelenPresident and CEOSep 07Sale42.3850,0002,118,846537,160Sep 07 05:46 PM
Matsuda MasaruSVP, General CounselSep 04Option Exercise0.006,883023,461Sep 07 05:42 PM
BIZZARI JEAN-PIERREDirectorAug 25Sale41.0135,0001,435,45552,544Aug 25 05:54 PM